<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1699-714X</journal-id>
<journal-title><![CDATA[Revista de la OFIL ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. OFIL·ILAPHAR]]></abbrev-journal-title>
<issn>1699-714X</issn>
<publisher>
<publisher-name><![CDATA[Organización de Farmacéuticos Ibero-Latinoamericanos]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1699-714X2020000300221</article-id>
<article-id pub-id-type="doi">10.4321/s1699-714x2020000300012</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Costo efectividad de insulina lispro protamina (NPL) vs. combinación de insulina NPH + insulina rápida]]></article-title>
<article-title xml:lang="en"><![CDATA[Cost effectiveness of lispro protamine insulin (NPL) vs. combination of NPH insulin + rapid insulin]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Villarreal Ríos]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Montoya Hernández]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vargas Daza]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cervantes Becerra]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Galicia Rodríguez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez González]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Unidad de Investigación Epidemiológica y en Servicios de Salud ]]></institution>
<addr-line><![CDATA[Querétaro ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Unidad de Medicina familiar No 9 ]]></institution>
<addr-line><![CDATA[Querétaro ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2020</year>
</pub-date>
<volume>30</volume>
<numero>3</numero>
<fpage>221</fpage>
<lpage>226</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1699-714X2020000300221&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1699-714X2020000300221&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1699-714X2020000300221&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Objetivo:  La estrategia farmacológica en el manejo de la diabetes tipo 2 incluye la insulina lispro protamina (NPL) vs. combinación de insulina NPH + insulina rápida. El análisis costo efectividad aborda el aspecto económico y el epidemiológico en el proceso de elección entre dos o más alternativas. El objetivo fue determinar el costo efectividad de la insulina lispro protamina (NPL) vs. combinación de insulina NPH + insulina rápida.  Métodos:  Estudio de costo efectividad en pacientes con diabetes tipo 2. Alternativa 1, usuarios de insulina lispro protamina (NPL), y 2, usuarios de insulina NPH + insulina rápida. Tamaño de muestra de 62 por grupo, técnica muestral aleatoria simple. El costo incluyó, costo unitario, intensidad de uso del servicio, costo promedio por insumo, costo promedio por servicio, y costo por tipo de alternativa (incluyó medicina familiar, laboratorio y medicamentos). La efectividad se determinó con el promedio de los resultados de glucosa realizados durante todo el año. El plan de análisis incluyó análisis costo efectividad y análisis costo efectividad incremental.  Resultados:  Costo promedio (estimado en pesos mexicanos) de la alternativa lispro protamina (NPL) $6,146.30 y NPH + insulina rápida $2,671.02. La NPH + insulina rápida tiene menor costo y mayor efectividad. El costo efectividad incremental identifica que con la alternativa NPH + insulina rápida existe ahorro de $158.98 por cada miligramo de glucosa por decilitro en relación a la alternativa lispro protamina (NPL).  Conclusion:  El resultado, bajo nuestras limitantes, sugiere mejor relación costo efectividad en insulina NPH + insulina rápida.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY  Objective:  Pharmacological strategies for the management of patients with type 2 diabetes include lispro protamine insulin (NPL) and NPH insulin + rapid insulin. The cost-effectiveness study addresses the economic and epidemiological aspects in the process of choosing between two or more alternatives. The objective is to determine the cost effectiveness of lispro protamine insulin (NPL) vs. combination of NPH insulin + rapid insulin.  Methods:  Cost effectiveness study in patients with type 2 diabetes. Alternative 1: lispro protamine insulin (NPL) and alternative 2: NPH insulin + rapid insulin. Sample size 62 per group, simple random sampling technique. Cost (estimated in Mexican pesos) included, unit cost, intensity of use of the service, average cost per input, average cost per service, and cost per type of alternative (including family medicine, laboratory and medication.) Effectiveness was determined with the average glucose results carried out throughout the year. Analysis plan included cost effectiveness analysis and incremental cost effectiveness analysis.  Results:  The total average cost of lispro protamine insulin (NPL) and NPH insulin + rapid insulin mixture was $6,146.30 and $2,671.02, respectively. The NPH insulin + rapid insulin mixture alternative has lower cost and greater effectiveness. According to the cost effectiveness analysis, with the NPH insulin + rapid insulin mixture alternative, there was a saving of $159.98 for each milligram of glucose per deciliter comparing to the lispro protamine insulin (NPL) alternative.  Conclusion:  According with our results, a better cost-effectiveness ratio was obtained in NPH insulin + rapid insulin.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Diabetes tipo 2]]></kwd>
<kwd lng="es"><![CDATA[insulina]]></kwd>
<kwd lng="es"><![CDATA[tratamiento]]></kwd>
<kwd lng="es"><![CDATA[costo efectividad]]></kwd>
<kwd lng="es"><![CDATA[NPH]]></kwd>
<kwd lng="es"><![CDATA[NPL]]></kwd>
<kwd lng="en"><![CDATA[Diabetes mellitus type 2]]></kwd>
<kwd lng="en"><![CDATA[insulin]]></kwd>
<kwd lng="en"><![CDATA[treatment]]></kwd>
<kwd lng="en"><![CDATA[cost effectiveness]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[Introduction: Standards of Medical Care in Diabetes-2019]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2019</year>
<numero>supplement 1</numero>
<issue>supplement 1</issue>
<page-range>S1-2</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2019</year>
<volume>42</volume>
<numero>supplement 1</numero>
<issue>supplement 1</issue>
<page-range>S13-28</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="">
<collab>International Diabetes Federation</collab>
<article-title xml:lang=""><![CDATA[The global picture. Chapter 3]]></article-title>
<source><![CDATA[IDF Diabetes atlas]]></source>
<year>2017</year>
<edition>Eighth edition</edition>
<page-range>40-65</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2019</year>
<volume>42</volume>
<numero>supplement 1</numero>
<issue>supplement 1</issue>
<page-range>S90-S102</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="">
<collab>Asociación Latinoamericana de Diabetes</collab>
<article-title xml:lang=""><![CDATA[Guías ALAD sobre el Diagnóstico, Control y Tratamiento de la Diabetes Mellitus Tipo 2 con Medicina Basada en Evidencia]]></article-title>
<source><![CDATA[ALAD]]></source>
<year>2013</year>
<page-range>73-88</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Dou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of the effect of glycemic control in type 2 diabetes outpatients treated with premixed and basal insulin monotherapy in China]]></article-title>
<source><![CDATA[Front Endocrinol]]></source>
<year>2018</year>
<volume>9</volume>
<page-range>639</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Howard]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Watts]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bolus insulin prescribing recommendations for patients with type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Federal Practitioner]]></source>
<year>2017</year>
<volume>34</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>S26-31</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<collab>Secretaría de Salud</collab>
<article-title xml:lang=""><![CDATA[Norma Oficial Mexicana NOM-015-SSA2-2010 Para la prevención, tratamiento y control de la Diabetes Mellitus. Segunda Sección]]></article-title>
<source><![CDATA[Diario Oficial]]></source>
<year>2010</year>
</nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[Glycemic Targets: Standards of Medical Care in Diabetes-2019]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2019</year>
<volume>42</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S61-70</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<collab>American Diabetes Association</collab>
<article-title xml:lang=""><![CDATA[Older Adults: Standards of Medical Care in Diabetes-2019]]></article-title>
<source><![CDATA[Diabetes Care]]></source>
<year>2019</year>
<volume>42</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S139-47</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villanueva-Egan]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Lezana-Fernández]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La importancia de la economía en las decisiones clínicas]]></article-title>
<source><![CDATA[Rev Conamed]]></source>
<year>2014</year>
<volume>19</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>128-31</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santamaría-Guasch]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[El papel de la economía de la salud en nuestro camino hacia la cobertura universal]]></article-title>
<source><![CDATA[Conamed]]></source>
<year>2015</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>70-3</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Farshchi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Oskuee]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rashed]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Aghili]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kebriaeezadeh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Esteghamati]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biphasic insulin aspart 30 vs. nph plus regular human insulin in type 2 diabetic patients: A cost-effectiveness study]]></article-title>
<source><![CDATA[BMC Endocrine Disorders]]></source>
<year>2016</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>35-44</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Souza]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vilela]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Coelho]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Rocha]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Régis]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cost-effectiveness of insulin analogs from the perspective of the brazilian public health system]]></article-title>
<source><![CDATA[Braz. J. Pharm. Sci]]></source>
<year>2017</year>
<volume>53</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moucheraud]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lenz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Latkovic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wirtz]]></surname>
<given-names><![CDATA[VJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The costs of diabetes treatment in low -and middle-income countries: a systematic review]]></article-title>
<source><![CDATA[BMJ Glob Health]]></source>
<year>2019</year>
<volume>4</volume>
</nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nabrdalik]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kwiendacz]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Sawczyn]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tomasik]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kukla]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Masierek]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy, safety, and quality of treatment satisfaction of premixed human and analogue insulin regimens in a large cohort of type 2 diabetic patients: progens benefit observational study]]></article-title>
<source><![CDATA[International Journal of Endocrinology]]></source>
<year>2018</year>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sheu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Ji]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Jabbar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lew]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ef&#64257;cacy and safety of premixed insulin analogs in Asian patients with type 2 diabetes: A systematic review]]></article-title>
<source><![CDATA[J Diabetes Investig]]></source>
<year>2017</year>
<volume>8</volume>
<page-range>518-34</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anyanwagu]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Mamza]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gordon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Donnelly]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Idris]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Premixed vs basal-bolus insulin regimen in type 2 diabetes: comparison of clinical outcomes from randomized controlled trials and real-world data]]></article-title>
<source><![CDATA[Diabet Med]]></source>
<year>2017</year>
<volume>34</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1728-36</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Nero]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparing clinical outcomes and costs for different treatment intensification approaches in patients with type 2 diabetes uncontrolled on basal insulin: adding glucagon-like peptide 1 receptor agonists versus adding rapid-acting insulin or increasing basal insulin dose]]></article-title>
<source><![CDATA[Endocr Pract]]></source>
<year>2017</year>
<volume>23</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1316-24</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jovanovic]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Peters]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Hardin]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes]]></article-title>
<source><![CDATA[Aging Clin Exp Res]]></source>
<year>2014</year>
<volume>26</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>115-21</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Durden]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Farr]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Gill]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and economic outcomes associated with the timing of initiation of basal insulin in patients with type 2 diabetes mellitus previously treated with oral antidiabetic drugs]]></article-title>
<source><![CDATA[Clin Ther]]></source>
<year>2016</year>
<volume>38</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>110-21</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Svensson]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Lak]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Fard]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Eliasson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Total costs of basal or premixed insulin treatment in 5077 insulin-naive type 2 diabetes patients: register-based observational study in clinical practice]]></article-title>
<source><![CDATA[Clin Diabetes Endocrinol]]></source>
<year>2015</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-6</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
